Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults

(2022) Pierre‐François Meyer et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

(2022) Nicholas J. Ashton et al.   EBioMedicine

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels

(2022) Malin Wennström et al.   Acta Neuropathologica Communications

Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

(2022) Denis S. Smirnov et al.   ACTA NEUROPATHOLOGICA

Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

(2022) Thomas K. Karikari et al.   Nature Reviews Neurology

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light

(2022) Suzanne E. Schindler et al.   NEUROLOGY

Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults

(2022) Michelle E. Farrell et al.   NEUROLOGY

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

(2022) Oskar Hansson et al.   Alzheimers & Dementia

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

(2022) Marta Milà-Alomà et al.   NATURE MEDICINE

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

(2022) Michael J. Pontecorvo et al.   JAMA Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

(2021) Shorena Janelidze et al.   Alzheimers & Dementia

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

(2021) Elisabeth H Thijssen et al.   LANCET NEUROLOGY

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays

(2021) Antoine Leuzy et al.   NEUROLOGY

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles

(2021) Stephan A. Kaeser et al.   ACTA NEUROPATHOLOGICA

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

(2021) Sherif Bayoumy et al.   Alzheimers Research & Therapy

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

(2021) Andréa L. Benedet et al.   JAMA Neurology

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease

(2020) Andréa L Benedet et al.   BRAIN

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

(2019) Gemma Salvadó et al.   Alzheimers Research & Therapy

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Determining clinically meaningful decline in preclinical Alzheimer disease

(2019) Philip S. Insel et al.   NEUROLOGY

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age

(2019) Tobey J Betthauser et al.   BRAIN

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL

(2018) Pierrick Bourgeat et al.   NEUROIMAGE

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis

(2016) Niklas Mattsson et al.   Nature Communications

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Amyloid burden and neural function in people at risk for Alzheimer's Disease

(2013) Sterling C. Johnson et al.   NEUROBIOLOGY OF AGING